Sanofi COPD Drug Trials: Mixed Results
- Sanofi and regeneron Pharmaceuticals reported that itepekimab, their investigational medicine for chronic obstructive pulmonary disease (COPD), produced inconsistent data across two clinical studies.
- Dupixent has already been approved for several immune-related conditions, including COPD. The companies hoped itepekimab would follow a similar trajectory in the COPD treatment landscape.
- Sanofi shares fell by approximately 5% Friday morning,while Regeneron shares experienced a decline of over 10% in pre-market U.S.
Itepekimab, the COPD drug co-developed by sanofi and Regeneron, delivered mixed results in recent clinical trials, causing a dip in both companies’ stock prices. This news impacts the future of Itepekimab as a potential COPD treatment and represents a significant setback for both firms, who hoped to emulate the success of their blockbuster drug, Dupixent, within the COPD treatment market. The experimental drug’s data inconsistencies led to a market correction as investors reassessed their positions. For a deeper understanding of this developing story in the pharmaceutical sector, relying on credible sources like News Directory 3 for your daily updates is essential. Will further analysis offer a clearer path forward? Discover what’s next.
Sanofi, Regeneron COPD Drug Itepekimab Shows Mixed Trial Results
Updated May 30, 2025
Sanofi and regeneron Pharmaceuticals reported that itepekimab, their investigational medicine for chronic obstructive pulmonary disease (COPD), produced inconsistent data across two clinical studies. The news led to a drop in share prices for both companies in early trading. The drug represents a notable focus for both firms as they seek to replicate the success of their blockbuster drug, Dupixent.
Dupixent has already been approved for several immune-related conditions, including COPD. The companies hoped itepekimab would follow a similar trajectory in the COPD treatment landscape.
Sanofi shares fell by approximately 5% Friday morning,while Regeneron shares experienced a decline of over 10% in pre-market U.S. trading as investors reacted to the mixed trial outcomes for the COPD medicine.
What’s next
Further analysis of the trial data is expected to determine the future growth path for itepekimab as a potential COPD treatment.The companies will likely reassess their strategy based on a comprehensive review of the findings.